BCR and Burkitt lymphoma: Therefore, NFATc1 activity is an integrated component of ‘tonic ́ BCR signaling, which is ‘hijacked’ from classical BCR signaling pathway and should be considered as an alternative target for therapeutic intervention in BL and as diagnostic feature.